Guides
What to Ask Before Your First Semaglutide Appointment
The FDA-approved label for Wegovy requires a real medical history screening before you ever get a prescription. Here's the exact list of questions a legitimate first appointment covers — and what it means if a clinic skips them.
A lot of “first appointments” at weight-loss clinics are really a sales call: a height and weight check, a card swipe, and a script. That’s not what the FDA-approved prescribing information for semaglutide actually calls for. The label carries a boxed warning and a specific list of conditions a prescriber is supposed to screen for before writing that prescription. If your first visit doesn’t touch any of it, that’s worth noticing.
The boxed warning question: thyroid cancer history
Wegovy’s label opens with a boxed warning — the FDA’s strongest label warning — for risk of thyroid C-cell tumors, based on findings in rodent studies where it’s unknown whether the same risk applies to humans. Because of that, the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A prescriber who never asks about your family’s thyroid cancer history before prescribing semaglutide is skipping the single question the label puts first.
What else the label says to screen for
Beyond the boxed warning, the prescribing information lists warnings a real intake should touch on, even briefly: a history of pancreatitis, gallbladder disease, hypoglycemia if you’re also on insulin or a sulfonylurea, kidney function (dehydration from nausea or vomiting can trigger acute kidney injury), any prior serious allergic reaction to semaglutide, diabetic retinopathy if you have type 2 diabetes, and a mental-health history — the label carries a specific warning on suicidal behavior and ideation. It also asks about pregnancy: semaglutide carries a pregnancy exposure registry because of potential fetal risk shown in animal studies, and weight loss itself offers no benefit during pregnancy. None of this requires a lecture. It’s a handful of direct questions, and a legitimate clinic asks them before you’re on the medication, not after a side effect shows up.
Two questions about the medication itself
Is this brand-name or compounded? With the tirzepatide and semaglutide shortages both resolved as of early 2025, routine bulk compounding of a drug that’s essentially a copy of Wegovy, Ozempic, Zepbound, or Mounjaro is no longer the legal default it briefly was — it’s restricted to documented, patient-specific medical needs under sections 503A and 503B of the FD&C Act. See our full breakdown of brand vs. compounded GLP-1s for what changed. If the answer is vague — “our proprietary blend,” “GLP-1 medication” with no brand name — ask again, more specifically.
Who is prescribing it, and can I check them? Every prescriber — MD, DO, NP, or PA — has an NPI number searchable in the federal NPI Registry (CMS). A clinic that names its prescriber and stands behind that name is giving you something you can verify independently in about thirty seconds. “Our medical team” is not a name.
Red flags the FDA itself warns about
The FDA’s own guidance on unapproved and unsafe GLP-1 sourcing lists specific telehealth warning signs: pricing that seems too good to be true, no licensed-doctor screening before you’re prescribed anything, no doctor available to answer questions once you have the medication, packaging that looks different from what a pharmacy normally provides, and labels with spelling errors or pharmacy addresses that don’t check out. Any one of these belongs on your list of reasons to walk out, not just your list of questions.
A short list to bring with you
Ask, plainly, in writing if possible: Is this brand-name or compounded medication? What’s your NPI number? Do I have a personal or family history of thyroid cancer that should rule this out? Do I have a history of pancreatitis or gallbladder disease? Am I pregnant or planning to be? A clinic that answers all five without hesitation is behaving the way the FDA’s own label expects a prescriber to behave.
See our full verification standard for how we screen clinics before listing them, and browse verified GLP-1 and peptide clinics in Houston.
Sources: U.S. Food and Drug Administration / National Library of Medicine, DailyMed, “WEGOVY (semaglutide) injection, solution” prescribing information, label revised April 2024 — Boxed Warning, Contraindications (§4), Warnings and Precautions (§5), and Pregnancy (§8.1). FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, content current as of September 1, 2026.
This article is independent editorial content, not medical advice. See our medical disclaimer.